Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery.
about
Recent Developments in Peptide-Based Nucleic Acid DeliverySequence-non-specific effects of RNA interference triggers and microRNA regulators.Quantitative evaluation of siRNA delivery in vivo.Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles.High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.Development of siRNA-probes for studying intracellular trafficking of siRNA nanoparticles.Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis.RNA interference-mediated gene silencing in murine T cells: in vitro and in vivo validation of proinflammatory target genesMultiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.Biological barriers to therapy with antisense and siRNA oligonucleotides.Delivery of RNAi therapeutics: work in progress.Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs.Delivering the promise of small ncRNA therapeutics.An aptamer intrinsically comprising 5-fluoro-2'-deoxyuridine for targeted chemotherapy.Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.Inflammation responsive logic gate nanoparticles for the delivery of proteins.Multiresponse strategies to modulate burst degradation and release from nanoparticles.Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier.Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor.
P2860
Q27487857-01A08861-51C9-4EE6-8F6B-B02EA01C91AAQ33566425-B6170313-A343-4B75-8961-C7968FD75973Q34370185-4E296055-7461-4608-8A51-EEAD79223634Q35103642-EAD66B79-428E-403F-911C-E31EAAA5C6D2Q35131115-9F28C550-6900-4D5C-BE6B-DDC7865EFFE6Q36472724-FF7C3819-0CF2-4F93-8254-2E6BFBA4FC96Q36649655-F618D801-3379-4741-8BFB-8A9CE742EEACQ36840109-11F4D89E-77E2-4AF4-8EE9-044E8BF79981Q37088608-6E1219FC-C8EF-47DB-9BD4-0DBB20AD4B45Q37193000-9CBC8078-0533-4912-AF00-20FDB6C9BCF0Q37347451-82A84CC3-FFB2-4194-ACDA-41ECCD37F299Q37378340-05B16B8E-C3B1-4C4A-B7B6-7D8658AA49D1Q38160246-9095F106-C2C1-48C0-A319-A07B9762B5AEQ38168518-7C64391A-6B05-41BB-B8FB-47A272216956Q38226666-C7926D93-1164-4B59-B689-6D7CD32A74D0Q38304827-DE40D1ED-26E5-4FD9-B784-AD927EF509B7Q38858347-75AE8158-8E10-448F-AB91-B7385B84668BQ38914284-19D1E618-2706-40C8-9178-D23834D716BEQ39657677-6C556731-7CAB-437F-8EBC-6AFE899B5C03Q39882078-008FE2F2-102F-457A-910A-062AD11DC67CQ39934164-08D9EB5B-7FFD-476A-ABE6-4A0F6E679110Q46641718-2FD6DB2E-1D18-4BC5-8749-C1ED47852CE5
P2860
Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cellular uptake and intracellu ...... rothioate-stimulated delivery.
@en
type
label
Cellular uptake and intracellu ...... rothioate-stimulated delivery.
@en
prefLabel
Cellular uptake and intracellu ...... rothioate-stimulated delivery.
@en
P2093
P2860
P1476
Cellular uptake and intracellu ...... rothioate-stimulated delivery.
@en
P2093
Alessandra Mescalchin
Anke Detzer
Georg Sczakiel
Maria Wecke
Marita Overhoff
Winfried Wünsche
P2860
P304
P356
10.1517/14712598.7.10.1531
P407
P577
2007-10-01T00:00:00Z